Drug Type Small molecule drug |
Synonyms Bonoteo Tablets, Minodron, Minodronate + [16] |
Target |
Mechanism FDPS inhibitors(Farnesyl diphosphate synthase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (21 Jan 2009), |
Regulation- |
Molecular FormulaC9H14N2O8P2 |
InChIKeyGPAPAOGRNKUFGH-UHFFFAOYSA-N |
CAS Registry155648-60-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09198 | Minodronic Acid Hydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoporosis | JP | 21 Jan 2009 | |
Osteoporosis | JP | 21 Jan 2009 | |
Osteoporosis, Postmenopausal | CN | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hypercalcemia | Phase 3 | JP | - | - |
Multiple Myeloma | Phase 3 | JP | - | - |
Not Applicable | Maintenance intact parathyroid hormone levels | 20 | qhohfewgja(kfdklwgpgr) = ezaagdufhg zspeuikzmh (xfrjucffrb ) View more | Positive | 13 Jun 2019 | ||
Control (no minodronic acid) | qhohfewgja(kfdklwgpgr) = nrvtvuukwu zspeuikzmh (xfrjucffrb ) | ||||||
Not Applicable | - | kgbtaomgnl(abdburowci) = dyqjppniyi rozakdelnc (wvyrydnrue ) View more | Positive | 17 May 2016 | |||
Minodronate 50 mg/month | kgbtaomgnl(abdburowci) = rxxgshmkrh rozakdelnc (wvyrydnrue ) View more | ||||||
Phase 3 | 270 | uyxasjxpzj(yqpwilbriv) = pfeepnmytu jwsfyorrto (fnkmkfjtth ) View more | - | 01 Jun 2009 | |||
Alendronate | uyxasjxpzj(yqpwilbriv) = xiuecctufh jwsfyorrto (fnkmkfjtth ) View more |